Shanghai Kaibao Pharmaceutical CO., LTD. is a China-based company principally engaged in research, development, manufacture and distribution of Chinese medicines. The Company's major products are clear away heat and toxic material injections, which are applied in treatment of upper respiratory tract infections, such as cold and pneumonia; pioglitazone hydrochloride tablets, which are applied in treatment of diabetes; captopril sustained-release tablets, which are adopted in treatment of hypertension, as well as doxofylline capsules, which are applied in treatment of asthma and other diseases. During the year ended December 31, 2010, the Company obtained approximately 99% of its total revenue from clear away heat and toxic material injections.